Immunome (IMNM) News Today $12.02 -0.42 (-3.38%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Immunome, Inc. (NASDAQ:IMNM) Short Interest UpdateImmunome, Inc. (NASDAQ:IMNM - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 9,790,000 shares, a decline of 8.2% from the November 15th total of 10,670,000 shares. Currently, 19.3% of the company's shares are sold short. Based on an average trading volume of 787,600 shares, the days-to-cover ratio is presently 12.4 days.December 16 at 6:06 AM | marketbeat.com3 Small-Cap Stocks With Big Growth Potential (IMNM)Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.December 13, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 217.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 442,477 shares of the company's stock after purchasing an additional 302,916 shares during the periDecember 12, 2024 | marketbeat.comImmunome: A Recently Acquired Lead Asset And A Small MarketDecember 11, 2024 | seekingalpha.comPoint72 Asset Management L.P. Buys 85,580 Shares of Immunome, Inc. (NASDAQ:IMNM)Point72 Asset Management L.P. increased its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 22.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 470,647 shares of the company's stock after purchasing an additional 85,580 shares during theDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Has $50.97 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)Janus Henderson Group PLC raised its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 10.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,488,121 shares of the company'December 6, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | businesswire.comImmunome to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | finance.yahoo.comImmunome Inc.November 26, 2024 | wsj.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Insider Acquires 15,805 Shares of StockNovember 26, 2024 | insidertrades.comImmunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from AnalystsImmunome, Inc. (NASDAQ:IMNM - Get Free Report) has been given an average rating of "Buy" by the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that havNovember 26, 2024 | marketbeat.comRobert Lechleider Buys 15,805 Shares of Immunome, Inc. (NASDAQ:IMNM) StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Robert Lechleider purchased 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.November 25, 2024 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) CTO Purchases 21,000 Shares of StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CTO Philip Tsai purchased 21,000 shares of the firm's stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.November 25, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) CEO Acquires $630,183.78 in StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The shares were bought at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the acquisition, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.November 25, 2024 | marketbeat.comImmunome files to sell 1.8M shares of common stock for holdersNovember 23, 2024 | markets.businessinsider.comVictory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM)Victory Capital Management Inc. raised its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,785 shares of the company's stock afterNovember 21, 2024 | marketbeat.comImmunome (IMNM) Receives a Buy from J.P. MorganNovember 20, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Immunome Lowered by Leerink PartnrsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 EPS estimates for shares of Immunome in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($2.23) per share for the year,November 18, 2024 | marketbeat.comWedbush Has Positive Forecast for Immunome FY2024 EarningsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Equities researchers at Wedbush upped their FY2024 earnings estimates for Immunome in a report released on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will earn ($2.11) per share for the year, up from their prNovember 18, 2024 | marketbeat.comWedbush Sticks to Their Buy Rating for Immunome (IMNM)November 15, 2024 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst DowngradeImmunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst DowngradeNovember 14, 2024 | marketbeat.comPiper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Thursday.November 14, 2024 | marketbeat.comPromising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative PipelineNovember 14, 2024 | markets.businessinsider.comImmunome Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comImmunome initiated with an Overweight at StephensNovember 9, 2024 | markets.businessinsider.comAnalyst Expectations For Immunome's FutureNovember 9, 2024 | benzinga.comStephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight RecommendationNovember 9, 2024 | msn.comImmunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy?Immunome (NASDAQ:IMNM) Shares Gap Up - Time to Buy?November 8, 2024 | marketbeat.comStephens Begins Coverage on Immunome (NASDAQ:IMNM)Stephens began coverage on Immunome in a research note on Friday. They set an "overweight" rating and a $30.00 price target for the company.November 8, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Up 8.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Trading Up 8.7% - Still a Buy?November 4, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages thNovember 1, 2024 | marketbeat.comImmunome Advances with Strategic Asset Acquisition and AgreementOctober 30, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short InterestImmunome, Inc. (NASDAQ:IMNM - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 10,920,000 shares, a decline of 15.2% from the September 30th total of 12,880,000 shares. Currently, 22.3% of the shares of the stock are short sold. Based on an average trading volume of 649,500 shares, the days-to-cover ratio is currently 16.8 days.October 29, 2024 | marketbeat.comWedbush Remains a Buy on Immunome (IMNM)October 25, 2024 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Stock Rating Reaffirmed by WedbushWedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a report on Friday.October 25, 2024 | marketbeat.comImmunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR SymposiumOctober 18, 2024 | businesswire.comCubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM)Cubist Systematic Strategies LLC reduced its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the company's stock after selOctober 15, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Grows Stock Position in Immunome, Inc. (NASDAQ:IMNM)The Manufacturers Life Insurance Company increased its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 52.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 166,928 shares of the company's stockOctober 10, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 6.1% - Time to Sell?Immunome (NASDAQ:IMNM) Stock Price Down 6.1% - Should You Sell?October 9, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 8, 2024 | finance.yahoo.comImmunome (NASDAQ:IMNM) Trading Up 3.5% - Here's What HappenedImmunome (NASDAQ:IMNM) Stock Price Up 3.5% - Should You Buy?October 8, 2024 | marketbeat.comImmunome Appoints Roee Shahar as Executive Vice President, CommercialOctober 8, 2024 | finance.yahoo.comSquarepoint Ops LLC Sells 45,843 Shares of Immunome, Inc. (NASDAQ:IMNM)Squarepoint Ops LLC decreased its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 38.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 73,929 shares of the company's stock after selling 45,843 shares during the period. SquarepoiOctober 7, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Buy" from AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages thOctober 7, 2024 | marketbeat.comCubist Systematic Strategies LLC Sells 54,117 Shares of Immunome, Inc. (NASDAQ:IMNM)Cubist Systematic Strategies LLC cut its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,421 shares of the company's stOctober 6, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comImmunome, Inc. (NASDAQ:IMNM) Stock Holdings Cut by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 76.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 385,067 shares of the company's stock after selling 1,256,833 shares during tOctober 2, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 4.7% Immunome (NASDAQ:IMNM) Stock Price Down 4.7%October 1, 2024 | marketbeat.comAxa S.A. Invests $2.17 Million in Immunome, Inc. (NASDAQ:IMNM)Axa S.A. acquired a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,688 shares of the company's stock, valued at approximately $2,174,000. AxaOctober 1, 2024 | marketbeat.com Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW IMNM Media Mentions By Week IMNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼1.310.72▲Average Medical News Sentiment IMNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼54▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRUS News Today TWST News Today ACAD News Today VCEL News Today MOR News Today SWTX News Today KYMR News Today ZLAB News Today GMTX News Today VERA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
